What Dosage of Semaglutide Is Used for Weight Loss?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no single semaglutide dosage used for weight loss — there is a range of labeled strengths, a labeled escalation built into the prescribing information, and a prescriber who decides where an individual patient sits within that structure. The Wegovy prescribing information lists injection strengths of 0.25, 0.5, 1, 1.7 and 2.4 mg, plus Wegovy HD at 7.2 mg, and tablet strengths of 1.5, 4, 9 and 25 mg. Which of those applies to you, and how you move between them, is a clinical decision documented on your pharmacy label — not something an article should hand you.

What the Label Actually Contains

Wegovy injection is supplied as single-dose pens at 0.25, 0.5, 1, 1.7 and 2.4 mg and as Wegovy HD at 7.2 mg, as single-dose syringes across the lower strengths, and as a single-patient-use Wegovy FlexTouch pen containing 9.6 mg/3 mL that delivers four 2.4 mg doses. Wegovy tablets come in 1.5, 4, 9 and 25 mg.

The label also contains a stepwise escalation. Its purpose is tolerability: gastrointestinal adverse reactions are the most common reason people struggle with this class, and starting low reduces them. The escalation is not a target to race through.

Ozempic, by contrast, is a type 2 diabetes product with no weight-management indication, and its strengths and escalation exist for glycemic control. Rybelsus and Ozempic tablets are likewise diabetes products. Comparing dosages across these labels is comparing different approvals.

Why the Right Dosage Is Not Simply the Highest One

Study 8 in the Wegovy label, a 72-week trial in 1,407 participants, reported mean weight changes of −18.8% at 7.2 mg, −15.5% at 2.4 mg and −3.9% with placebo. So higher labeled dosages did produce greater mean reduction in that trial.

A mean, however, describes a group. Individual tolerability varies substantially, and a dosage that produces persistent vomiting is not delivering an advantage — it is delivering a reason to stop. The label directs that maintenance dosage selection account for both response and tolerability.

There is also a floor effect on the other side. STEP 1 reported a mean change of −14.9% at 2.4 mg over 68 weeks versus −2.4% with placebo, which is a large effect by any historical standard for weight management pharmacotherapy.

Escalation Is a Clinical Process, Not a Calendar

The reason this article does not print a week-by-week schedule is that the schedule is only half the instruction. The other half is what to do when a step is not tolerated, and that half is individual.

Your prescriber is making judgements about how quickly to move, whether to hold at a strength, whether to step back down, and whether to stop. Those judgements draw on your symptom pattern, your other medications, your kidney function and your history.

The FDA has documented why improvising here is risky. It has received adverse event reports that may relate to compounded semaglutide or tirzepatide prescribed in doses beyond what is in the approved label — more product per dose, more frequent dosing, or faster escalation — with some events serious enough to require hospitalization.

Compounded Preparations Do Not Have a Labeled Dosage

A compounded semaglutide preparation has no FDA-reviewed prescribing information of its own. The FDA states that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing.

The agency has also received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide — patients measuring and self-administering incorrect doses, and in some cases clinicians miscalculating doses.

That is a specific, documented failure mode of this category, and it is the reason FDA encourages patients to talk with their prescriber or compounder about how the intended dose is measured and administered. Those conversations belong with the people holding your prescription.

What Gets Measured Besides the Number on the Vial

Reasonable follow-up looks at more than weight: blood pressure, glycemic markers where relevant, lipid panel, symptom burden, and whether nutrition is adequate now that total intake has fallen.

Protein adequacy and resistance training matter during active weight loss because some of the weight lost is lean mass. A registered dietitian is the right referral for setting targets, and many prescribers make it routinely.

Both weight-management indications are written as adjuncts to a reduced-calorie diet and increased physical activity. That phrasing is in the indication because the trials were run that way, and it is a reminder that the dosage question is only one input among several.

Questions Worth Asking Your Prescriber

Which product am I actually on, and does it hold a weight-management indication? What strength am I at now, and what is the plan for the next step? What symptoms should prompt a call rather than waiting for the next appointment?

What happens if I cannot tolerate the next step? How will we decide when I have reached a maintenance strength? What does long-term look like, given that the Wegovy indication includes maintaining weight reduction long term?

Those questions get you a plan you can actually follow. A number pulled from an article does not, because it carries none of the context that makes it safe.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What semaglutide strengths are approved for weight management?

The Wegovy prescribing information lists injection strengths of 0.25, 0.5, 1, 1.7 and 2.4 mg, plus Wegovy HD at 7.2 mg, and tablet strengths of 1.5, 4, 9 and 25 mg. Which strength applies to an individual, and how they move between them, is decided by the prescriber and documented on the pharmacy label rather than set by a general rule.

Is 2.4 mg still the standard maintenance dosage?

It remains a labeled maintenance strength, but it is no longer the labeled maximum. Wegovy HD at 7.2 mg once weekly was approved March 19, 2026. Study 8 in the label, running 72 weeks in 1,407 participants, reported mean weight changes of −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9% with placebo. Selection between them is a clinical decision.

Why does the dosage start low?

Tolerability. Gastrointestinal adverse reactions — nausea, vomiting, diarrhea, abdominal pain and constipation — are the most common adverse reactions in this class and the most common reason people discontinue. A stepwise escalation built into the label reduces those symptoms compared with starting at a maintenance strength, which is why the structure exists at all.

Does Ozempic have a weight-loss dosage?

No. Ozempic is approved for glycemic control in adults with type 2 diabetes, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and for kidney outcomes in adults with type 2 diabetes and chronic kidney disease. It has no weight-management indication, so its labeled strengths are not weight-loss dosages. Wegovy is the semaglutide product with that indication.

How is dosing handled with a compounded preparation?

A compounded preparation has no FDA-reviewed prescribing information of its own, and the agency does not review compounded drugs for safety, effectiveness or quality before marketing. The FDA has received reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, and encourages patients to discuss measurement and administration directly with their prescriber or compounder.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.